DorsaVi Limited reported a 5.8% rise in revenue to $1.59 million for FY26 but saw its loss after tax balloon by 462% to $8.52 million, reflecting heavy investment in next-gen semiconductor and AI technologies alongside a $5 million capital raise.
- Revenue increased modestly to $1.59 million
- Loss after tax surged 462% to $8.52 million
- Completed $5 million capital raising to fund RRAM and neuromorphic programs
- Progressed RRAM semiconductor development with NTU and ITRI partners
- Expanded wearable sensor platform as commercial testbed
Sharp Loss Growth Amid Strategic Tech Investments
DorsaVi Limited (ASX:DVL) reported a 5.8% increase in revenue to $1.59 million for the year ended 30 June 2026, but the headline figure obscures a dramatic 462% jump in the company’s loss after tax to $8.52 million. This steep increase reflects DorsaVi’s accelerated spending on its Resistive Random-Access Memory (RRAM) semiconductor development and neuromorphic intellectual property acquisition, as well as expanded share-based payments and amortisation of acquired assets.
The company’s sales revenue declined 11% to just over $1 million, impacted by timing of customer projects and a shift towards building larger commercial relationships. Despite the loss, DorsaVi bolstered its balance sheet through a $5 million strategic placement in late 2025, raising capital to fund its semiconductor and sensor technology programs alongside general working capital needs. Net assets rose to $4.34 million at year-end, supported by $2.12 million in cash reserves.
Advancing RRAM Development with Asian Research Partners
DorsaVi’s semiconductor ambitions are anchored by a structured development program in collaboration with Nanyang Technological University (NTU) in Singapore and Taiwan’s Industrial Technology Research Institute (ITRI). The program covers the full RRAM development pathway, including device and material-stack development, process integration, Compute-in-Memory circuit design, and validation chip development targeting an advanced 22-nanometre platform.
Initial device characterisation at the 180-nm node has been completed, serving as a validation step before scaling down to the 22-nm node. The company has successfully passed key Back-End-of-Line compatibility tests for three RRAM material stacks, mitigating integration risks with commercial CMOS manufacturing. Circuit and layout designs for the RRAM-CMOS validation chip, featuring Compute-in-Memory architecture, are also complete. Following year-end, DorsaVi progressed to tape-out and physical manufacturing of this first integrated validation chip, marking a critical milestone in translating design into silicon.
Neuromorphic IP Acquisition Adds Processing Dimension
In February 2026, DorsaVi acquired an exclusive worldwide licence to a neuromorphic processing-in-memory portfolio from Technion Research & Development Foundation and Neurofabrica Pty Ltd, settled via 80 million shares. This acquisition complements the RRAM program by adding circuit-level and system architecture capabilities aimed at reducing data movement and enabling localized processing.
Together, these technologies underpin DorsaVi’s Ultra-Edge Intelligence strategy, which aims to embed sensing, decision-making, and action capabilities directly on devices. This approach promises lower latency, reduced power consumption, and decreased reliance on cloud connectivity, with potential applications spanning intelligent sensing, robotics, exoskeletons, medical devices, and industrial systems.
Wearable Sensor Platform Remains Strategic Commercial Testbed
DorsaVi’s established wearable sensor business continues to be a cornerstone of its strategy, providing an FDA-cleared platform with over a decade of clinical and workplace applications. The company is advancing Sensor V6.5, which integrates on-device processing and feedback capabilities, allowing real-time analysis and response without cloud dependence. This development aligns with the Physical AI vision of devices that can sense, decide, and act autonomously.
The sensor platform not only serves existing clinical and workplace customers but also acts as a proving ground for the company’s semiconductor innovations, linking near-term commercial markets with long-term technology development.
Commercial Growth and Leadership Refresh
On the commercial front, DorsaVi is focusing on expanding multi-site clinical partnerships across the US and growing its global workplace market through sensor and Video AI solutions. The company plans to adopt a distributor-led hybrid model to extend market reach while managing internal costs.
Leadership changes included the appointment of Mathew Regan as Group CEO in November 2025, bringing experience in scaling AI-driven healthcare businesses. Andrew Ronchi transitioned to lead the sensor business, maintaining deep clinical and technical expertise.
Auditor Flags Material Uncertainty on Going Concern
DorsaVi’s financial statements were audited by Horizon Nexus with an unqualified opinion. However, the auditor’s report highlighted a material uncertainty related to going concern, reflecting the risks inherent in commercialising early-stage semiconductor technology and the company’s ongoing losses.
The directors remain confident in the company’s ability to continue as a going concern, citing a strong history of capital raisings, including $5.16 million raised in August and September 2025, and $545,455 from option exercises during FY26. They emphasize disciplined capital allocation and milestone-driven execution as key to navigating the path to profitability.
What to Watch Next
DorsaVi’s near-term focus will be on completing manufacturing and electrical characterisation of its RRAM-CMOS validation chip, optimising material stacks and Compute-in-Memory architecture, and advancing the neuromorphic IP integration. Commercially, the rollout of Sensor V6.5 and expansion through distributor partnerships will be critical. Investors should monitor technical milestones, capital management, and commercial traction as indicators of progress toward sustainable shareholder value.
Bottom Line?
DorsaVi’s heavy investment in pioneering RRAM and neuromorphic technologies is reshaping its business but deepens losses, underscoring the high-risk, high-reward nature of semiconductor commercialisation.
Questions in the middle?
- Will DorsaVi’s RRAM validation chip deliver the performance needed to attract commercial foundry partners?
- How quickly can the Sensor V6.5 platform gain traction in clinical and workplace markets under the new distributor model?
- What capital raising strategies will the company pursue to sustain its expanded tech development without diluting shareholders excessively?